ADHANSIA XR
Live / Registered — Registered (as of 28 Jan 2020)
What this means for you
Registered since 28 Jan 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87982478
- Registration number
- 5973730
- Mark type
- Stylized text
- Filed
- 16 Jan 2018
- Published for opposition
- 28 Aug 2018
- Registered
- 28 Jan 2020
- Attorney of record
- Fara S. Sunderji
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely, attention deficit disorder, attention deficit hyperactivity disorder, hyperactivity, and executive functioning disorder
Owner
- PURDUE PHARMA L.P., STAMFORD, CT, US
- PURDUE PHARMA L.P., STAMFORD, CT, US
- Purdue Pharma, Pickering, Ontario, CA
- Purdue Pharma, Pickering, Ontario, CA
Prosecution history
- 28 Jan 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 28 Jan 2020 — REGISTERED-PRINCIPAL REGISTER
- 21 Dec 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 Dec 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 18 Dec 2019 — DIVISIONAL PROCESSING COMPLETE
- 11 Dec 2019 — DIVISIONAL REQUEST RECEIVED
- 11 Dec 2019 — TEAS REQUEST TO DIVIDE RECEIVED
- 27 Sept 2019 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 27 Sept 2019 — NON-FINAL ACTION E-MAILED
- 27 Sept 2019 — SU - NON-FINAL ACTION - WRITTEN
- 20 Sept 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 23 Aug 2019 — USE AMENDMENT FILED
- 18 Sept 2019 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 23 Aug 2019 — TEAS STATEMENT OF USE RECEIVED
- 27 Feb 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED